Showing 2762 results
- Media Release /In pivotal study, everolimus reduced risk of disease progression by 52%; showed 11.0-month median progression-free survival vs 3.9 months for placebo[1] Advanced, progressive, nonfunctional…
- In The News /Novartis CEO Vas Narasimhan discusses how to improve pandemic preparedness at the CNBC Evolve Global Summit.
- Pulse Update /
- Pulse Update /
- Pulse Update /
- Pulse Update /
- Pulse Update /
- Pulse Update /
- Pulse Update /
- Story /
In a medical treatment facility on the Thai-Burmese border, 21 patients infected with malaria recently participated in a clinical trial.
Pagination
- ‹ Previous page
- 1
- …
- 247
- 248
- 249
- 250
- 251
- 252
- 253
- …
- 277
- › Next page